About this trial
Pain constitutes the predominant motive prompting individuals to seek emergency medical attention, accounting for 80% of admissions to emergency departments. Presently, it is imperative to employ expeditious and efficacious analgesia-sedation methodologies, obviating the necessity for intravenous administration, while ensuring the secure delivery of pharmaceutical agents. The objective of this study is to assess the feasibility and comfort of nebulized intranasal or facial aerosol administration of Fentanyl through the implementation of a pharmacokinetic/pharmacodynamic (PK/PD) study
Eligibility criteria
Qualifiers
Age ≥ 18 years and < 68 years
BMI between 19 and 29 kg/m²
Affiliation to a social security scheme
Adult who has read and understood the information letter and signed the consent form
Disqualifiers
Weight < 50 kg
Taking long-term painkillers or narcotics
Sharp pain
Stable chronic pain (>3 months, with or without long-term treatment)
Trial design
Treatments tested in this trial
- Fentanyl - Inhalation by facial nebulization
- Fentanyl - Nebulisation